Guy Jerusalem

发表

Guy Jerusalem, Roland Hustinx, R. Hustinx, 2006 .

O. S. Zhukova, Guy Jerusalem, Robert Millham, 2012 .

Asporin Is a Fibroblast-Derived TGF-β1 Inhibitor and a Tumor Suppressor Associated with Good Prognosis in Breast Cancer

Pierre Drion, Guy Jerusalem, Andrei Turtoi, 2015, PLoS medicine.

Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis

Thomas Bachelot, Jie Zhang, Julie Glanville, 2013, Breast Cancer Research and Treatment.

Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis.

Roland Hustinx, Tarik Belhocine, Guy Jerusalem, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Scott D Flamm, Patrizio Lancellotti, Thor Edvardsen, 2014, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

Guy Jerusalem, Cristina Saura, J. Baselga, 2014, Clinical Cancer Research.

Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial

Didier Verhoeven, Guy Jerusalem, M. Lichinitser, 2013, Journal of the National Cancer Institute.

A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer

Oriana Ciani, Carla Rognoni, Lajos Pusztai, 2015, Breast Cancer Research and Treatment.

Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers

Raphaël Marée, Vincent Bours, Stephane Wenric, 2015, BMC Cancer.